# CED Cannabis Science Digest: Pregnancy Risk Perception Signals > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pregnancy-safety-beliefs-cannabis-risk-perception/ > **Published:** 2026-07-05T07:19:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:49:52-04:00 > **Clinical Summary:** Explore pregnancy safety beliefs cannabis signals from surveys and studies on risk perception, use trends, and expectancies among women and veterans. --- CED Clinical Relevance #52 Evidence-Limited but Worth Tracking Today’s full evidence report covered the strongest prenatal cannabis paper from the scan. This companion digest preserves three additional lower-certainty human signals on pregnancy risk perception, women of childbearing age, and cannabis expectancies among Veterans. Clinical Insight | CED Clinic Today’s strongest [cannabis science](https://cedclinic.com/biphasic-effects-of-cannabis/) item was better handled as a standalone full evidence report on prenatal cannabis exposure and neurodevelopment. What remained useful after that selection was a smaller set of human papers that sharpen counseling rather than settle efficacy. One nationwide U.S. survey suggests many women of childbearing age rate cannabis during pregnancy as safer than alcohol or tobacco and often connect use to symptom relief. A second Swiss trend analysis suggests [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) has risen over decades among women of childbearing age alongside other shifts in health and care utilization. A third Veterans study suggests cannabis expectancies are more predictive between people than within people over time, which matters for how clinicians interpret belief-driven use. None of these papers proves a treatment effect. Together, they help explain how cannabis beliefs and exposure risk can become normalized before a clinician ever reaches a product-level conversation. DigestPregnancyRisk PerceptionVeteransCounseling Audience Patients, caregivers, obstetric and mental-health clinicians, addiction readers, and evidence-focused readers trying to separate observational belief signals from stronger intervention evidence. Primary Topic Three verified human cannabis signals on pregnancy beliefs, women of childbearing age, and cannabis expectancies in Veterans. Source [Read the full study](https://pubmed.ncbi.nlm.nih.gov/42401977/) Table of Contents - [CED Cannabis Science Digest: 3 Pregnancy, Expectations, and Risk-Perception Signals Worth Watching](#CED_Cannabis_Science_Digest_3_Pregnancy_Expectations_and_Risk-Perception_Signals_Worth_Watching) - [How to Read Three Human Cannabis-Context Papers Without Turning Them Into Treatment Proof](#How_to_Read_Three_Human_Cannabis-Context_Papers_Without_Turning_Them_Into_Treatment_Proof)[A Better Reading Order for Risk-Perception Signals](#A_Better_Reading_Order_for_Risk-Perception_Signals) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Beliefs About Safety Need Evidence, Not Just Familiarity](#Beliefs_About_Safety_Need_Evidence_Not_Just_Familiarity) - [Pregnancy Counseling Starts With Perceived Risk](#Pregnancy_Counseling_Starts_With_Perceived_Risk) - [Normalization Can Outrun Evidence](#Normalization_Can_Outrun_Evidence) - [Expectancies Matter in Cannabis Behavior](#Expectancies_Matter_in_Cannabis_Behavior) - [Context Studies Need Small Claims](#Context_Studies_Need_Small_Claims) - [Cannabis Use Often Arrives With a Story About Relief](#Cannabis_Use_Often_Arrives_With_a_Story_About_Relief) - [Design Limits Stay Attached to the Result](#Design_Limits_Stay_Attached_to_the_Result) - [What Would Upgrade These Signals](#What_Would_Upgrade_These_Signals) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## CED Cannabis Science Digest: 3 Pregnancy, Expectations, and Risk-Perception Signals Worth Watching Today’s full evidence report covered the strongest prenatal cannabis paper from the scan. This digest keeps three additional human signals visible: a U.S. survey on pregnancy safety beliefs, a Swiss trend study showing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) rising among women of childbearing age, and a Veteran cohort analysis showing how cannabis expectancies track use patterns between people over time. What This Study Teaches Us These papers are useful because they all operate in the counseling layer of [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) rather than the treatment-proof layer. One asks how women of childbearing age perceive cannabis risk during pregnancy. One tracks broad health and lifestyle changes in reproductive-age women over three decades in Switzerland, including rising [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). One examines how cannabis expectancies relate to cannabis and alcohol use among Veterans over time. Read together, they show why cannabis conversations can feel settled to patients even when the evidence is still observational and incomplete. Why This Matters Risk perception often moves faster than evidence. If patients increasingly view cannabis as relatively safe during pregnancy, or if use patterns rise in reproductive-age populations while expectancies stay positive, counseling has to become more specific and more evidence-aware. These papers matter because they show where those perception gaps can start. Study Snapshot Post Type Evidence digest using the canonical CED layout Batch ID bf5c575729924c94 Curated Set 3 verified, nonduplicate human cannabis-context items Editorial Decision The day’s strongest paper was published separately as a full report. This digest preserves additional lower-certainty signals that still matter for counseling and evidence interpretation. Item 1 U.S. survey of pregnancy safety beliefs about cannabis versus alcohol and tobacco Item 2 Swiss 30-year trend analysis in women of childbearing age including rising cannabis use Item 3 Veteran longitudinal analysis of cannabis expectancies and use patterns Primary Dates July 4, 2026; June 17, 2026; July 3, 2026 Content Lanes Safety Signal; Research Brief; Research Brief Main Takeaway Useful for counseling and risk framing, not treatment proof Related Reading 3 verified live CED Clinic internal links Clinical Bottom Line The practical value of this digest is better risk communication. These papers do not prove cannabis efficacy or predict one patient outcome, but they show how expectations, normalization, and exposure patterns can shape cannabis decisions before stronger clinical evidence arrives. Digest Contents - [Digest Card 1 | Pregnancy Safety Beliefs in U.S. Women of Childbearing Age](#digest-card-2-digest-card-1-pregnancy-safety-beliefs-in-u-s-women-of-childbearing-age) - [Digest Card 2 | A 30-Year Swiss Trend Signal in Women of Childbearing Age](#digest-card-3-digest-card-2-a-30-year-swiss-trend-signal-in-women-of-childbearing-age) - [Digest Card 3 | Cannabis Expectancies Among Veterans Over Time](#digest-card-4-digest-card-3-cannabis-expectancies-among-veterans-over-time) Why These Items Belong Together The strongest paper from today’s scan already received a full standalone evidence report. What remained were three human studies that still deserved preservation because they help explain how cannabis risk gets interpreted, normalized, or misunderstood in real life. That is why this digest works as a companion rather than a replacement. It keeps additional signals visible without pretending that surveys or expectancy models answer the same question as a stronger clinical evidence synthesis. Digest Card 1 | Pregnancy Safety Beliefs in U.S. Women of Childbearing Age Authors / source / date / lane: S. G. Casavant and colleagues, Journal of [Cannabis Research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), July 4, 2026, Safety Signal. What was investigated: a nationwide online survey of 622 U.S. women of childbearing age that compared beliefs about the safety of cannabis use during pregnancy with beliefs about alcohol and tobacco, while also asking about prior prenatal use patterns and reasons for use. What it appeared to find: among respondents who had been pregnant, 25.9% reported cannabis use during pregnancy, compared with 23.6% for tobacco and 8.2% for alcohol, and participants rated prenatal cannabis use as safer than alcohol or tobacco. Symptom relief for nausea, anxiety, sleep disturbance, and pain was a common reason for use. Limitations and uncertainty: this was a self-reported online survey, not a pregnancy-outcome study. It does not prove the reported beliefs are accurate, does not measure actual fetal outcomes, and may not generalize to every U.S. population. Why it is noteworthy: the paper is useful because it shows how risk communication can already be drifting. If many respondents see cannabis as relatively safe in pregnancy, the counseling challenge begins before any exposure is reduced. Digest Card 2 | A 30-Year Swiss Trend Signal in Women of Childbearing Age Authors / source / date / lane: Iliana Calabretti and colleagues, Swiss Medical Weekly, June 17, 2026, Research Brief. What was investigated: repeated Swiss Health Survey data from 1992 through 2022 in women aged 15 to 49, examining health status, care utilization, contraception, substance use, and broader lifestyle changes over time. What it appeared to find: the paper reported an upward trend in illicit-drug use, particularly cannabis, over the three-decade period, alongside higher educational attainment, more psychological-health consultations, higher BMI, and shifting medication and contraception patterns. Limitations and uncertainty: this is a broad population trend paper, not a pregnancy-outcome study and not a cannabis-specific exposure analysis. It cannot say whether rising cannabis use caused a specific maternal or child outcome, and its relevance may not transfer cleanly outside Switzerland. Why it is noteworthy: the study helps contextualize why prenatal and periconception cannabis counseling is becoming more important. A substance can become more common in reproductive-age populations long before the evidence conversation catches up. Digest Card 3 | Cannabis Expectancies Among Veterans Over Time Authors / source / date / lane: Benjamin L. Berey and colleagues, Journal of Studies on Alcohol and Drugs, July 3, 2026, Research Brief. What was investigated: a three-wave secondary analysis of 361 post-9/11 Veterans with lifetime cannabis use, testing whether urgency traits, cannabis expectancies, and quantity or frequency of use tracked within or between people over 12 months. What it appeared to find: positive cannabis expectancies were associated with higher cannabis use frequency and quantity between people, while negative expectancies tracked with lower cannabis use. The expected within-person mediation pattern was not supported over time. Limitations and uncertainty: this was not a clinical trial and not a general-population study. It focused on Veterans, used self-report measures, and cannot prove that changing expectancies alone will change cannabis use behavior or clinical outcomes. Why it is noteworthy: expectancy research matters because cannabis decisions are often shaped by belief as much as by evidence. If positive expectancies track use between people, counseling has to address how cannabis is imagined, not just how it is dosed. How Strong Is This Evidence? All three items are journal-published human studies with verified source metadata, but none is a randomized intervention trial. One is a survey of pregnancy beliefs, one is a population trend analysis, and one is a longitudinal expectancy model. That is enough for a bounded digest on risk perception and counseling context, not for treatment-proof claims. Where This Paper Deserves Skepticism Readers should keep the design limits visible. Surveys can amplify selection and recall bias. Broad trend studies can show co-movement without causation. Expectancy models can clarify patterns without telling clinicians exactly how to change outcomes for a specific patient. What This Paper Does Not Show This digest does not prove that cannabis is safe in pregnancy, that rising cannabis use among women of childbearing age predicts a specific obstetric or pediatric outcome, or that positive cannabis expectancies directly cause later use behavior in a way that any one counseling script can reverse. It also does not justify a treatment decision without individualized clinical context. How This Fits With the Broader Clinical Conversation A patient can reach cannabis use through many paths: symptom relief, normalization, peer experience, shifting public messaging, or an internal belief that cannabis is less risky than alternatives. These studies sit in those earlier stages of decision-making. That is why they matter even without proving efficacy. They make the pre-treatment context more visible and help clinicians understand what kind of conversation may need to happen before a product recommendation is ever discussed. Dr. Caplan’s Take *The pregnancy-beliefs survey is the most clinically urgent item here because it shows how far perceived safety may drift from evidence quality. If a patient believes cannabis is safer in pregnancy than alcohol or tobacco, the counseling conversation has to start there rather than with abstract literature summaries.* *The Swiss and Veteran papers matter for a related reason. They remind us that cannabis use lives inside broader social patterns and expectancy structures. Those are not excuses for weak counseling. They are reasons to make counseling sharper.* What a Careful Reader Should Take Away Use this digest to get more precise about what is driving cannabis use or reassurance: symptom relief, normalization, population trend, or expectancy. The reward is better counseling, not stronger certainty. Evidence Interpretation Guide ## How to Read Three Human Cannabis-Context Papers Without Turning Them Into Treatment Proof These three papers all involve real people, but they answer different questions. One is about pregnancy safety beliefs, one is about long-run population trends in women of childbearing age, and one is about cannabis expectancies among Veterans. A useful reading habit is to ask what the paper can improve today. These studies can sharpen risk framing and questions, but they cannot settle product efficacy or define one clinical rule. ### A Better Reading Order for Risk-Perception Signals **Start With Study Design**A belief survey, a population trend analysis, and a longitudinal expectancy model do not answer the same question as a trial or a stronger clinical synthesis. **Ask Whether the Main Signal Is About Exposure, Belief, or Behavior**The pregnancy paper is mainly about perceived safety, the Swiss paper is mainly about long-run exposure context, and the Veteran paper is mainly about expectancies and use patterns. **Keep the Population in View**Women of childbearing age, pregnant respondents, and post-9/11 Veterans bring different baseline risks, reasons for use, and counseling needs. **Do Not Convert Context Signals Into Product Claims**These papers can improve counseling and evidence framing, but they do not prove that cannabis should be started, continued, or trusted for a condition on the basis of these designs alone. Key Reading Question Is the paper primarily teaching me about outcome risk, social normalization, or the beliefs that can shape cannabis use behavior? The Question Patients Usually Need Answered Does this digest tell me cannabis is safe or effective, or does it mostly show why beliefs and exposure patterns can become more confident than the underlying evidence? The Bottom Line The best use of these papers is to improve risk communication and patient questioning, not to inflate confidence about treatment outcomes. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview A pregnant patient, public-health reader, Veteran clinician, or skeptic will take something different from this batch. These eight lenses keep the papers useful without letting observational context data impersonate stronger clinical certainty. #### Beliefs About Safety Need Evidence, Not Just Familiarity If cannabis feels familiar or gentler than other substances, that does not automatically make it safe in pregnancy or harmless in a particular clinical context. These papers are useful because they show how that feeling of familiarity can emerge before stronger evidence is available. Lens takeaway Comfort with cannabis is not the same thing as proof of safety. #### Pregnancy Counseling Starts With Perceived Risk The U.S. survey suggests many patients may come to pregnancy counseling already believing cannabis is safer than alcohol or tobacco. That means clinicians need to ask directly what the patient believes, why they are using it, and which symptoms they are trying to manage. Lens takeaway Belief assessment is part of prenatal risk counseling. #### Normalization Can Outrun Evidence The Swiss trend paper does not prove one cannabis-specific harm, but it does show how use can become more common in reproductive-age populations over time. When exposure rises faster than evidence literacy, public-health messaging has to work harder. Lens takeaway Population trends can raise counseling urgency even before stronger causal evidence arrives. #### Expectancies Matter in Cannabis Behavior The Veteran paper suggests positive cannabis expectancies travel with higher cannabis use between people, even if the short-run within-person mechanism was not supported in the model. That makes expectancy language clinically relevant even when it does not answer every outcome question. Lens takeaway Belief structure is part of the behavioral landscape clinicians have to address. #### Context Studies Need Small Claims These are useful studies, but only if their claims stay bounded. Surveys, trends, and expectancy models can reveal where the conversation is drifting without proving how a product performs clinically. The right skeptical move is calibration, not dismissal. Lens takeaway These papers deserve attention, but not inflation. #### Cannabis Use Often Arrives With a Story About Relief Pregnancy-related symptom relief, broad normalization, and positive expectancies all make cannabis feel more intuitively reasonable to users. That means mental-health and counseling work has to address the narrative around use, not only the product itself. Lens takeaway The motive and the story around use both matter clinically. #### Design Limits Stay Attached to the Result Self-report bias, population specificity, and non-causal design all limit what these studies can tell us. A useful digest keeps those limits in the foreground rather than hiding them after a striking statistic. That is especially important in pregnancy and mental-health contexts where readers may overgeneralize quickly. Lens takeaway The design tells you how loudly the result should be spoken. #### What Would Upgrade These Signals Stronger next-step work would connect belief patterns, exposure trends, and expectancy structures to prospective clinical outcomes and better confounder control. Until then, these studies are best treated as counseling and framing tools rather than outcome-settling evidence. Lens takeaway The upgrade path is prospective human outcome research, not stronger rhetoric. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CED+Cannabis+Science+Digest%3A+3+Pregnancy%2C+Expectations%2C+and+Risk-Perception+Signals+Worth+Watching&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-july-5-2026-pregnancy-risk-perception-signals%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-july-5-2026-pregnancy-risk-perception-signals%2F) [BlueSky](https://bsky.app/intent/compose?text=CED+Cannabis+Science+Digest%3A+3+Pregnancy%2C+Expectations%2C+and+Risk-Perception+Signals+Worth+Watching%20https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-july-5-2026-pregnancy-risk-perception-signals%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Attitudes and beliefs regarding cannabis use during pregnancy compared to alcohol and tobacco: a nationwide survey of U.S. women of childbearing age.](https://pubmed.ncbi.nlm.nih.gov/42401977/) Related Reading at CED Clinic Continue exploring the evidence [CED Cannabis Science Digest: 3 Safety Signals Worth Watching](https://cedclinic.com/prenatal-cannabis-safety-signals-2026-digest/) Earlier prenatal safety context for readers who want more on pregnancy-related cannabis caution signals. [Read prenatal safety context](https://cedclinic.com/prenatal-cannabis-safety-signals-2026-digest/) [CED Cannabis Science Digest: 3 CUD, Dosing, and Neurobiology Signals Worth Watching](https://cedclinic.com/2026-cannabis-use-disorder-research-cud-dosing-neurobiology/) Related addiction and interpretation context on [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and how evidence can be overread. [Read the CUD context digest](https://cedclinic.com/2026-cannabis-use-disorder-research-cud-dosing-neurobiology/) [Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies.](https://cedclinic.com/relationships-cannabis-mental-disorders-evidence-coherence/) A broader CED review on where cannabis-mental-health evidence looks stronger and where causality remains unsettled. [Read the mental-health review](https://cedclinic.com/relationships-cannabis-mental-disorders-evidence-coherence/) ## Frequently Asked Questions Why is this a digest instead of another standalone full [cannabis science](https://cedclinic.com/biphasic-effects-of-cannabis/) report? Because today’s strongest paper was already handled as a full evidence report, while these three remaining items were more useful as a bounded companion digest about risk perception and counseling context. Does the pregnancy-beliefs survey prove cannabis is safer than alcohol or tobacco in pregnancy? No. It shows that many respondents perceived cannabis that way. It does not test fetal or child outcomes and does not validate the belief. Why does the pregnancy-beliefs survey still matter clinically? Because counseling has to begin with what patients actually believe. If cannabis is already seen as relatively safe, clinicians need to address that directly. Does the Swiss trend paper prove cannabis caused worse reproductive outcomes? No. It is a broad population trend analysis that includes rising cannabis use among many other changing health and lifestyle factors. Why include a broad women-of-childbearing-age trend study in a cannabis digest? Because it helps explain why cannabis counseling in reproductive-age populations is becoming more important even when stronger cannabis-specific outcome data remain incomplete. Does the Veteran expectancy paper prove that changing beliefs will change cannabis use? No. It shows associations between expectancies and use patterns, especially between people, but it does not prove a simple intervention effect. Are any of these three papers treatment proof? No. One is a pregnancy-belief survey, one is a broad population trend analysis, and one is an expectancy model in Veterans. How should clinicians use a digest like this? As a way to improve counseling precision. These papers help clinicians understand what beliefs, population trends, and expectancy structures may already be shaping cannabis use. Should patients change treatment based on this digest alone? No. This digest is educational context, not individualized medical advice, and none of the three papers is strong enough to justify a treatment change on its own. What would stronger research add beyond this digest? Stronger work would connect beliefs and exposure patterns to prospective clinical outcomes, better confounder control, and more representative human populations. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).